Ahola Tero, Couderc Therese, Ng Lisa F P, Hallengärd David, Powers Ann, Lecuit Marc, Esteban Mariano, Merits Andres, Roques Pierre, Liljeström Peter
1 Department of Food and Environmental Sciences, University of Helsinki , Helsinki, Finland .
Vector Borne Zoonotic Dis. 2015 Apr;15(4):250-7. doi: 10.1089/vbz.2014.1681.
Currently, there are no licensed vaccines or therapies available against chikungunya virus (CHIKV), and these were subjects discussed during a CHIKV meeting recently organized in Langkawi, Malaysia. In this review, we chart the approaches taken in both areas. Because of a sharp increase in new data in these fields, the present paper is complementary to previous reviews by Weaver et al. in 2012 and Kaur and Chu in 2013 . The most promising antivirals so far discovered are reviewed, with a special focus on the virus-encoded replication proteins as potential targets. Within the vaccines in development, our review emphasizes the various strategies in parallel development that are unique in the vaccine field against a single disease.
目前,尚无针对基孔肯雅病毒(CHIKV)的获批疫苗或疗法,这些都是最近在马来西亚兰卡威举办的一次基孔肯雅病毒会议上讨论的主题。在本综述中,我们梳理了这两个领域所采取的方法。由于这些领域的新数据急剧增加,本文对韦弗等人在2012年以及考尔和朱在2013年发表的先前综述起到补充作用。我们对迄今发现的最有前景的抗病毒药物进行了综述,特别关注病毒编码的复制蛋白作为潜在靶点。在正在研发的疫苗方面,我们的综述强调了针对单一疾病在疫苗领域并行开发的各种独特策略。